The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

AT1 Receptor Antagonists-Global Market Insights and Sales Trends 2025

AT1 Receptor Antagonists-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1819300

No of Pages : 102

Ask Your Query
Synopsis
AT1 receptor antagonists are a group of pharmaceuticals that modulate the renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They block the activation of AT1receptors, preventing the binding of angiotensin II.
The global AT1 Receptor Antagonists market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of AT1 Receptor Antagonists in various end use industries. The expanding demands from the Hypertension, Cardiovascular Diseases, Kidney Diseases and Other, are propelling AT1 Receptor Antagonists market. Valsartan, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Telmisartan segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for AT1 Receptor Antagonists market, driven by demand from China, the second largest economy with some signs of stabilising, the AT1 Receptor Antagonists market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for AT1 Receptor Antagonists, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global AT1 Receptor Antagonists market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global AT1 Receptor Antagonists market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, AT1 Receptor Antagonists sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of AT1 Receptor Antagonists covered in this report include Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb and Bayer, etc.
The global AT1 Receptor Antagonists market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Global AT1 Receptor Antagonists market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global AT1 Receptor Antagonists market, Segment by Type:
Valsartan
Telmisartan
Losartan
Irbesartan
Azilsartan
Olmesartan
Global AT1 Receptor Antagonists market, by Application
Hypertension
Cardiovascular Diseases
Kidney Diseases
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of AT1 Receptor Antagonists manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of AT1 Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 AT1 Receptor Antagonists Market Overview
1.1 AT1 Receptor Antagonists Product Overview
1.2 AT1 Receptor Antagonists Market Segment by Type
1.2.1 Valsartan
1.2.2 Telmisartan
1.2.3 Losartan
1.2.4 Irbesartan
1.2.5 Azilsartan
1.2.6 Olmesartan
1.3 Global AT1 Receptor Antagonists Market Size by Type
1.3.1 Global AT1 Receptor Antagonists Market Size Overview by Type (2018-2029)
1.3.2 Global AT1 Receptor Antagonists Historic Market Size Review by Type (2018-2023)
1.3.3 Global AT1 Receptor Antagonists Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America AT1 Receptor Antagonists Sales Breakdown by Type (2018-2023)
1.4.2 Europe AT1 Receptor Antagonists Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific AT1 Receptor Antagonists Sales Breakdown by Type (2018-2023)
1.4.4 Latin America AT1 Receptor Antagonists Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa AT1 Receptor Antagonists Sales Breakdown by Type (2018-2023)
2 Global AT1 Receptor Antagonists Market Competition by Company
2.1 Global Top Players by AT1 Receptor Antagonists Sales (2018-2023)
2.2 Global Top Players by AT1 Receptor Antagonists Revenue (2018-2023)
2.3 Global Top Players by AT1 Receptor Antagonists Price (2018-2023)
2.4 Global Top Manufacturers AT1 Receptor Antagonists Manufacturing Base Distribution, Sales Area, Product Type
2.5 AT1 Receptor Antagonists Market Competitive Situation and Trends
2.5.1 AT1 Receptor Antagonists Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by AT1 Receptor Antagonists Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in AT1 Receptor Antagonists as of 2022)
2.7 Date of Key Manufacturers Enter into AT1 Receptor Antagonists Market
2.8 Key Manufacturers AT1 Receptor Antagonists Product Offered
2.9 Mergers & Acquisitions, Expansion
3 AT1 Receptor Antagonists Status and Outlook by Region
3.1 Global AT1 Receptor Antagonists Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global AT1 Receptor Antagonists Historic Market Size by Region
3.2.1 Global AT1 Receptor Antagonists Sales in Volume by Region (2018-2023)
3.2.2 Global AT1 Receptor Antagonists Sales in Value by Region (2018-2023)
3.2.3 Global AT1 Receptor Antagonists Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global AT1 Receptor Antagonists Forecasted Market Size by Region
3.3.1 Global AT1 Receptor Antagonists Sales in Volume by Region (2024-2029)
3.3.2 Global AT1 Receptor Antagonists Sales in Value by Region (2024-2029)
3.3.3 Global AT1 Receptor Antagonists Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global AT1 Receptor Antagonists by Application
4.1 AT1 Receptor Antagonists Market Segment by Application
4.1.1 Hypertension
4.1.2 Cardiovascular Diseases
4.1.3 Kidney Diseases
4.1.4 Other
4.2 Global AT1 Receptor Antagonists Market Size by Application
4.2.1 Global AT1 Receptor Antagonists Market Size Overview by Application (2018-2029)
4.2.2 Global AT1 Receptor Antagonists Historic Market Size Review by Application (2018-2023)
4.2.3 Global AT1 Receptor Antagonists Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America AT1 Receptor Antagonists Sales Breakdown by Application (2018-2023)
4.3.2 Europe AT1 Receptor Antagonists Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific AT1 Receptor Antagonists Sales Breakdown by Application (2018-2023)
4.3.4 Latin America AT1 Receptor Antagonists Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa AT1 Receptor Antagonists Sales Breakdown by Application (2018-2023)
5 North America AT1 Receptor Antagonists by Country
5.1 North America AT1 Receptor Antagonists Historic Market Size by Country
5.1.1 North America AT1 Receptor Antagonists Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America AT1 Receptor Antagonists Sales in Volume by Country (2018-2023)
5.1.3 North America AT1 Receptor Antagonists Sales in Value by Country (2018-2023)
5.2 North America AT1 Receptor Antagonists Forecasted Market Size by Country
5.2.1 North America AT1 Receptor Antagonists Sales in Volume by Country (2024-2029)
5.2.2 North America AT1 Receptor Antagonists Sales in Value by Country (2024-2029)
6 Europe AT1 Receptor Antagonists by Country
6.1 Europe AT1 Receptor Antagonists Historic Market Size by Country
6.1.1 Europe AT1 Receptor Antagonists Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe AT1 Receptor Antagonists Sales in Volume by Country (2018-2023)
6.1.3 Europe AT1 Receptor Antagonists Sales in Value by Country (2018-2023)
6.2 Europe AT1 Receptor Antagonists Forecasted Market Size by Country
6.2.1 Europe AT1 Receptor Antagonists Sales in Volume by Country (2024-2029)
6.2.2 Europe AT1 Receptor Antagonists Sales in Value by Country (2024-2029)
7 Asia-Pacific AT1 Receptor Antagonists by Region
7.1 Asia-Pacific AT1 Receptor Antagonists Historic Market Size by Region
7.1.1 Asia-Pacific AT1 Receptor Antagonists Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific AT1 Receptor Antagonists Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific AT1 Receptor Antagonists Sales in Value by Region (2018-2023)
7.2 Asia-Pacific AT1 Receptor Antagonists Forecasted Market Size by Region
7.2.1 Asia-Pacific AT1 Receptor Antagonists Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific AT1 Receptor Antagonists Sales in Value by Region (2024-2029)
8 Latin America AT1 Receptor Antagonists by Country
8.1 Latin America AT1 Receptor Antagonists Historic Market Size by Country
8.1.1 Latin America AT1 Receptor Antagonists Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America AT1 Receptor Antagonists Sales in Volume by Country (2018-2023)
8.1.3 Latin America AT1 Receptor Antagonists Sales in Value by Country (2018-2023)
8.2 Latin America AT1 Receptor Antagonists Forecasted Market Size by Country
8.2.1 Latin America AT1 Receptor Antagonists Sales in Volume by Country (2024-2029)
8.2.2 Latin America AT1 Receptor Antagonists Sales in Value by Country (2024-2029)
9 Middle East and Africa AT1 Receptor Antagonists by Country
9.1 Middle East and Africa AT1 Receptor Antagonists Historic Market Size by Country
9.1.1 Middle East and Africa AT1 Receptor Antagonists Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa AT1 Receptor Antagonists Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa AT1 Receptor Antagonists Sales in Value by Country (2018-2023)
9.2 Middle East and Africa AT1 Receptor Antagonists Forecasted Market Size by Country
9.2.1 Middle East and Africa AT1 Receptor Antagonists Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa AT1 Receptor Antagonists Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Introduction and Business Overview
10.1.3 Pfizer AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Pfizer AT1 Receptor Antagonists Products Offered
10.1.5 Pfizer Recent Development
10.2 Novartis
10.2.1 Novartis Company Information
10.2.2 Novartis Introduction and Business Overview
10.2.3 Novartis AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Novartis AT1 Receptor Antagonists Products Offered
10.2.5 Novartis Recent Development
10.3 Merck
10.3.1 Merck Company Information
10.3.2 Merck Introduction and Business Overview
10.3.3 Merck AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Merck AT1 Receptor Antagonists Products Offered
10.3.5 Merck Recent Development
10.4 Astra Zeneca
10.4.1 Astra Zeneca Company Information
10.4.2 Astra Zeneca Introduction and Business Overview
10.4.3 Astra Zeneca AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Astra Zeneca AT1 Receptor Antagonists Products Offered
10.4.5 Astra Zeneca Recent Development
10.5 Jhonson and Johnson
10.5.1 Jhonson and Johnson Company Information
10.5.2 Jhonson and Johnson Introduction and Business Overview
10.5.3 Jhonson and Johnson AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Jhonson and Johnson AT1 Receptor Antagonists Products Offered
10.5.5 Jhonson and Johnson Recent Development
10.6 Eli Lilly
10.6.1 Eli Lilly Company Information
10.6.2 Eli Lilly Introduction and Business Overview
10.6.3 Eli Lilly AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Eli Lilly AT1 Receptor Antagonists Products Offered
10.6.5 Eli Lilly Recent Development
10.7 Sanofi
10.7.1 Sanofi Company Information
10.7.2 Sanofi Introduction and Business Overview
10.7.3 Sanofi AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Sanofi AT1 Receptor Antagonists Products Offered
10.7.5 Sanofi Recent Development
10.8 Bristol-Myers Squibb
10.8.1 Bristol-Myers Squibb Company Information
10.8.2 Bristol-Myers Squibb Introduction and Business Overview
10.8.3 Bristol-Myers Squibb AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Bristol-Myers Squibb AT1 Receptor Antagonists Products Offered
10.8.5 Bristol-Myers Squibb Recent Development
10.9 Bayer
10.9.1 Bayer Company Information
10.9.2 Bayer Introduction and Business Overview
10.9.3 Bayer AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Bayer AT1 Receptor Antagonists Products Offered
10.9.5 Bayer Recent Development
10.10 GSK
10.10.1 GSK Company Information
10.10.2 GSK Introduction and Business Overview
10.10.3 GSK AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2018-2023)
10.10.4 GSK AT1 Receptor Antagonists Products Offered
10.10.5 GSK Recent Development
10.11 Teva Pharmaceutical
10.11.1 Teva Pharmaceutical Company Information
10.11.2 Teva Pharmaceutical Introduction and Business Overview
10.11.3 Teva Pharmaceutical AT1 Receptor Antagonists Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Teva Pharmaceutical AT1 Receptor Antagonists Products Offered
10.11.5 Teva Pharmaceutical Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 AT1 Receptor Antagonists Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 AT1 Receptor Antagonists Industrial Chain Analysis
11.4 AT1 Receptor Antagonists Market Dynamics
11.4.1 AT1 Receptor Antagonists Industry Trends
11.4.2 AT1 Receptor Antagonists Market Drivers
11.4.3 AT1 Receptor Antagonists Market Challenges
11.4.4 AT1 Receptor Antagonists Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 AT1 Receptor Antagonists Distributors
12.3 AT1 Receptor Antagonists Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock